TG Forum Logo TG Forum Logo

Should we be lowering TG levels in the range between 150 and 500 mg/dL, and if so, how? Setting the scene

You are here: Home > Expert Meetings

Gerald Watts, University of Western Australia, Perth, highlights the challenges of designing outcome studies for novel TG-lowering agents in patients with mild-to-moderate hypertriglyceridaemia, including in those treated with a GLP-1 agonist.

Please login or create a FREE account to view this content

View more presentations from this meeting >

Educational Supporters of the 10th Closed Scientific Expert Meeting of the Editorial Board

Principal supporters:

Guest supporters:

Educational partners and supporters

Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc. Arrowhead Pharmaceuticals
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc. Ionis Logo
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc. Kowa Logo